Abhishek Singh, PhD
Advanced Heart Failure and Transplant Cardiology · Morristown, NJNPI 1790010874
Payments from drug & device makers
Across 984 payments — averaging $447.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$235K
- Impulse Dynamics (USA) Inc.$71K
- Actelion Pharmaceuticals US, Inc.$65K
- Merck$36K
- Bayer$13K
- Novartis$12K
- plus $9K from 32 others
What the payments were for
- Consulting fees$40,28014%
- Speaking & faculty fees$209,44174%
- Travel & lodging$14,3355%
- Food & beverage$18,1576%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 234 | $234,670 |
| Impulse Dynamics (USA) Inc. | 57 | $70,791 |
| Actelion Pharmaceuticals US, Inc. | 150 | $64,905 |
| Merck | 56 | $35,826 |
| Bayer | 51 | $12,982 |
| Novartis | 99 | $12,309 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 44 | $3,457 |
| Abbott | 42 | $1,380 |
| Boehringer Ingelheim | 62 | $952 |
| Alnylam Pharmaceuticals Inc. | 37 | $583 |
| Pfizer | 37 | $549 |
| AstraZeneca | 27 | $474 |
| Amgen | 16 | $230 |
| Daxor Corporation | 4 | $185 |
| E.r. Squibb & Sons, L.L.C. | 12 | $181 |
| Lexicon Pharmaceuticals, Inc. | 9 | $161 |
| Abiomed | 1 | $136 |
| Johnson & Johnson | 3 | $135 |
| Baxter Healthcare | 4 | $119 |
| Scpharmaceuticals Inc. | 5 | $94 |
| Vifor Pharma, Inc. | 6 | $88 |
| Bridgebio Pharma, Inc. | 4 | $76 |
| Boston Scientific | 3 | $66 |
| Endotronix, Inc. | 2 | $57 |
| Cvrx, Inc. | 2 | $44 |
| Akcea Therapeutics, Inc. | 3 | $42 |
| Zimvie Inc. | 1 | $41 |
| Novo Nordisk | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Argon Medical Devices, Inc. | 1 | $27 |
| Medtronic | 1 | $24 |
| Acist Medical Systems, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$440,762 in reported general payments places this provider in the 95th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
See all advanced heart failure and transplant cardiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 251 | $6,044,170 |
| Tyvaso DpiTreprostinil | 120 | $2,797,342 |
| OpsumitMacitentan | 87 | $1,126,160 |
| AdempasRiociguat | 50 | $695,363 |
| Orenitram ErTreprostinil Diolamine | 55 | $246,300 |
| EntrestoSacubitril/Valsartan | 121 | $160,544 |
| FarxigaDapagliflozin Propanediol | 64 | $71,830 |
| EliquisApixaban | 49 | $53,821 |
| Sildenafil Citrate | 82 | $30,933 |
| JardianceEmpagliflozin | 20 | $28,429 |
| VerquvoVericiguat | 12 | $11,004 |
| Eplerenone | 83 | $6,983 |
| Tadalafil | 19 | $2,110 |
| Spironolactone | 183 | $1,487 |
| Torsemide | 59 | $1,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $549 | $6,097,991300 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $64,905 | $1,126,16087 claims |
| BayerAdempas | $12,982 | $695,36350 claims |
| NovartisEntresto | $12,309 | $160,544121 claims |
| AstraZenecaFarxiga | $474 | $71,83064 claims |
| Boehringer IngelheimJardiance | $952 | $28,42920 claims |
| MerckVerquvo | $35,826 | $11,00412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
Other advanced heart failure and transplant cardiology in Morristown
- Saad AhmadMorristown$368K
- Mark ZuckerMorristown$251K
- Raul FloresMorristown$11K
- Robert MohapatraSewell$281K
- Kumar SatyaHackensack$167K
- Kulpreet BarnBarnegat$146K
- Kanika ModyHackensack$116K
- Juan Ortega LegaspiCherry Hill$88K
- Saurabh KapoorEnglewood$85K
- Ahmed SeliemCamden$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.